Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There’s no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.
Market Dynamics:
Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2020, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.
In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
Key features of the study:
Detailed Segmentation:
Table of Contents:
*Browse 24 market data tables and 28 figures on "Global Migraine Therapeutic Market” - forecast to 2028
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients